Pseudoephedrine; require manufacturers to pay fees to National Association of Drug Diversion Investigators to support NPLE.
Summary
HB1463 amends Mississippi’s controlled sales rules for pseudoephedrine and ephedrine products, which are common ingredients in over-the-counter cold medicines but also used in the illicit manufacture of methamphetamine. The bill keeps the existing purchase limits and pharmacy controls in place, including the requirement that pharmacies use the National Precursor Log Exchange (NPLEx) before completing a sale, verify purchaser identification, maintain transaction logs, and deny sales when the system generates a stop-sale alert. It also preserves the existing prescription exemption for legitimate prescriptions and the misdemeanor penalties for violations.
The main new provision requires manufacturers of pseudoephedrine or ephedrine products sold in or into Mississippi to pay monthly fees, beginning October 1, 2025, to the National Association of Drug Diversion Investigators to support administration of NPLEx. The association sets the fee levels, and manufacturers must provide proof of payment to the State Board of Pharmacy upon request. The bill also continues to require law enforcement access to NPLEx data and maintains the special rule that residents of states requiring a prescription for these products may only purchase them with a valid prescription in Mississippi.
Impact
HB1463 updates Section 73-21-124 of the Mississippi Code by adding a manufacturer-fee funding mechanism for NPLEx while leaving the state’s pseudoephedrine/ephedrine sales restrictions largely intact. It affects pharmacies, retailers, manufacturers, the Mississippi Board of Pharmacy, law enforcement, and the National Association of Drug Diversion Investigators. The bill does not change the core purchase limits, logging requirements, or criminal penalties, but it shifts part of the administrative cost of the tracking system to manufacturers.
Sentiment
The bill appears to have broad bipartisan support and little visible opposition in the recorded votes. It passed the House unanimously, 118-0, and the Senate by a wide margin, 50-1. That voting pattern suggests general agreement with the bill’s anti-diversion and public-safety goals, especially the use of NPLEx to monitor pseudoephedrine sales and deter methamphetamine precursor diversion.
Contention
The most notable point of potential contention is the new monthly fee requirement imposed on manufacturers, since it creates an ongoing financial obligation tied to sales in Mississippi and gives NADAI authority to set fee levels. Another possible issue is the continued reliance on NPLEx and the stop-sale system, which can affect pharmacy operations and customer access when transactions are blocked. However, the available record shows no committee debate and very little floor opposition, indicating that any concerns were limited or not strongly expressed in the final legislative process.